1
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Zhang Z, Miao L, Xin X, Zhang J, Yang S,
Miao M, Kong X and Jiao B: Underexpressed CNDP2 participates in
gastric cancer growth inhibition through activating the MAPK
signaling pathway. Mol Med. 20:17–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Correa P: Gastric cancer: Overview.
Gastroenterol Clin North Am. 42:211–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Aushev VN, Zborovskaya IB, Laktionov KK,
et al: Comparisons of microRNA patterns in plasma before and after
tumor removal reveal new biomarkers of lung squamous cell
carcinoma. PLoS One. 8:e786492013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Szabó DR, Luconi M, Szabó PM, et al:
Analysis of circulating microRNAs in adrenocortical tumors. Lab
Invest. 94:331–339. 2014. View Article : Google Scholar : PubMed/NCBI
|
8
|
Yao Y, Suo AL, Li ZF, et al: MicroRNA
profiling of human gastric cancer. Mol Med Rep. 2:963–970.
2009.PubMed/NCBI
|
9
|
Cao W, Yang W, Fan R, et al: miR-34a
regulates cisplatin-induce gastric cancer cell death by modulating
PI3K/AKT/survivin pathway. Tumour Biol. 35:1287–1295. 2014.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y and
Zheng X: miR-34a inhibits migration and invasion by down-regulation
of c-Met expression in human hepatocellular carcinoma cells. Cancer
Lett. 275:44–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
11
|
He M, Gao L, Zhang S, Tao L, Wang J, Yang
J and Zhu M: Prognostic significance of miR-34a and its target
proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and
DLBCL. Gastric Cancer. 17:431–441. View Article : Google Scholar : PubMed/NCBI
|
12
|
Gao W, Xu J, Liu L, Shen H, Zeng H and Shu
Y: A systematic-analysis of predicted miR-21 targets identifies a
signature for lung cancer. Biomed Pharmacother. 66:21–28. 2012.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Smith L, Tanabe LK, Ando RJ, et al:
Overview of BioCreative II gene mention recognition. Genome Biol. 9
(Suppl 2):S22008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Dahlquist KD, Salomonis N, Vranizan K,
Lawlor SC and Conklin BR: GenMAPP, a new tool for viewing and
analyzing microarray data on biological pathways. Nat Genet.
31:19–20. 2002. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ogata H, Goto S, Fujibuchi W and Kanehisa
M: Computation with the KEGG pathway database. Biosystems.
47:119–128. 1998. View Article : Google Scholar : PubMed/NCBI
|
16
|
Mewes HW, Albermann K, Heumann K, Liebl S
and Pfeiffer F: MIPS: A database for protein sequences, homology
data and yeast genome information. Nucleic Acids Res. 25:28–30.
1997. View Article : Google Scholar : PubMed/NCBI
|
17
|
Hooper SD and Bork P: Medusa: A simple
tool for interaction graph analysis. Bioinformatics. 21:4432–4433.
2005. View Article : Google Scholar : PubMed/NCBI
|
18
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
19
|
Volinia S, Calin GA, Liu CG, et al: A
microRNA expression signature of human solid tumors defines cancer
gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Rosenfeld N, Aharonov R, Meiri E, et al:
MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol.
26:462–469. 2008. View
Article : Google Scholar : PubMed/NCBI
|
21
|
Wang F, Sun GP, Zou YF, Hao JQ, Zhong F
and Ren WJ: MicroRNAs as promising biomarkers for gastric cancer.
Cancer Biomark. 11:259–267. 2012.PubMed/NCBI
|
22
|
Hermeking H: The miR-34 family in cancer
and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Cha YH, Kim NH, Park C, Lee I, Kim HS and
Yook JI: MiRNA-34 intrinsically links p53 tumor suppressor and Wnt
signaling. Cell Cycle. 11:1273–1281. 2012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Kolligs FT, Bommer G and Göke B:
Wnt/beta-catenin/tcf signaling: A critical pathway in
gastrointestinal tumorigenesis. Digestion. 66:131–144. 2002.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Mishra L, Shetty K, Tang Y, Stuart A and
Byers SW: The role of TGF-beta and Wnt signaling in
gastrointestinal stem cells and cancer. Oncogene. 24:5775–5789.
2005. View Article : Google Scholar : PubMed/NCBI
|
26
|
Endoh H, Yatabe Y, Kosaka T, Kuwano H and
Mitsudomi T: PTEN and PIK3CA expression is associated with
prolonged survival after gefitinib treatment in EGFR-mutated lung
cancer patients. J Thorac Oncol. 1:629–634. 2006. View Article : Google Scholar : PubMed/NCBI
|
27
|
Musgrove EA, Caldon CE, Barraclough J,
Stone A and Sutherland RL: Cyclin D as a therapeutic target in
cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
28
|
Inman GJ: Linking Smads and
transcriptional activation. Biochem J. 386:e1–e3. 2005. View Article : Google Scholar : PubMed/NCBI
|